Acute Lymphopenia and Recovery With Prophylactic Pelvic Nodal Radiotherapy in Oligometastatic Prostate Cancer: Interim Results From the Prospective PROLONG2 Cohort
Cancer Medicine · 2026-11 · 15 (11)
DOI: 10.1002/cam4.72466 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 02.11.2026. Verfasst von Xin Qi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Peking University First Hospital, Beijing, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Lymphopenia, Lymphatic Irradiation. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: 2023 National Science and Technology Major Programme for Cancer, Cardiovascular, Respiratory and Metabolic Disease Prevention and Treatment Research, Beijing WeiKang Public Welfare Foundation, Capital Health Development Research Programme.
Abstract (Originalsprache)
Background
Prophylactic pelvic nodal radiotherapy (PRT) aims to eradicate occult pelvic nodal disease in oligometastatic prostate cancer but increases lymphocyte exposure. Its early hematologic safety and lymphocyte recovery when added to radiotherapy to the prostate/prostate region and all imaging‐visible metastases remain uncertain.
Methods
PROLONG2 is an ongoing, single‐center, prospective, nonrandomized, two‐arm cohort study. This interim analysis included 133 patients who completed radiotherapy: 86 with PRT and 47 without PRT (NPRT). The key safety endpoint was acute grade ≥ 3 lymphopenia. Other assessments included lymphocyte status at 6–12 months and acute hematologic and genitourinary/gastrointestinal toxicities. The association was estimated by multivariable logistic regression adjusted for age, clinical N stage, and hormone‐sensitivity status. Survival analysis was exploratory.
Results
Acute grade ≥ 3 lymphopenia occurred in 43/86 PRT patients (50.0%) and 8/47 NPRT patients (17.0%). PRT remained associated with acute grade ≥ 3 lymphopenia after adjustment (OR, 4.03; 95% CI, 1.55–11.54; p = 0.006). At 6–12 months, grade ≥ 2 lymphopenia occurred in 18.2% versus 16.7%, and grade ≥ 3 lymphopenia in 1.3% versus 2.4%, respectively. Among evaluable PRT patients with acute grade ≥ 3 lymphopenia, 25/38 (65.8%) recovered to grade 0–1. No acute grade ≥ 3 genitourinary/gastrointestinal toxicity occurred. Progression‐free survival data remained immature, with only eight events reported.
Conclusions
PRT was associated with markedly more acute lymphopenia, but persistent severe lymphopenia was uncommon and the between‐group difference was substantially attenuated at 6–12 months. Continued prospective hematologic surveillance and mature survival data are needed to determine PRT's benefit–risk profile. Trial Registration Chinese Clinical Trial Registry: ChiCTR2400083776
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Peking University First Hospital, Beijing, China.
- Department of Urology, Peking University First Hospital, Beijing, China.
ORCID-Profile: Xin Qi, Hewei Wang, Yi Song, Yu Fan, Xianshu Gao, Hongzhen Li
Förderung
- 2023 National Science and Technology Major Programme for Cancer, Cardiovascular, Respiratory and Metabolic Disease Prevention and Treatment Research
- Beijing WeiKang Public Welfare Foundation
- Capital Health Development Research Programme
- National High Level Hospital Clinical Research Funding
- Peking University-Golden Resource "Tengyun Clinical Research Program"
Zitieren
APA
Qi, X., Wang, H., Zhang, H., Ren, X., Ma, M., Li, X., Zhang, W., He, Z., Song, Y., Shen, C., Yu, W., Fan, Y., Gao, X., & Li, H. (2026). Acute Lymphopenia and Recovery With Prophylactic Pelvic Nodal Radiotherapy in Oligometastatic Prostate Cancer: Interim Results From the Prospective PROLONG2 Cohort. Cancer Medicine, 15(11). https://doi.org/10.1002/cam4.72466
Vancouver
Qi X, Wang H, Zhang H, Ren X, Ma M, Li X, et al. Acute Lymphopenia and Recovery With Prophylactic Pelvic Nodal Radiotherapy in Oligometastatic Prostate Cancer: Interim Results From the Prospective PROLONG2 Cohort. Cancer Medicine. 2026;15(11). doi:10.1002/cam4.72466
BibTeX
@article{Qi2026,
author = {Qi, Xin and Wang, Hewei and Zhang, Huan and Ren, Xueying and Ma, Mingwei and Li, Xiaoying and Zhang, Wanqi and He, Zhisong and Song, Yi and Shen, Cheng and Yu, Wei and Fan, Yu and Gao, Xianshu and Li, Hongzhen},
title = {Acute Lymphopenia and Recovery With Prophylactic Pelvic Nodal Radiotherapy in Oligometastatic Prostate Cancer: Interim Results From the Prospective PROLONG2 Cohort},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {11},
doi = {10.1002/cam4.72466}
}
EUVIMED